JAMA Cardiology published a University of Oxford led study validating CaRi-Heart FAI-Score coronary inflammation measurement from routine CCTA in 19,110 patients. Very high coronary inflammation in patients with a calcium score of zero was associated with a 14.1x higher risk of cardiovascular death, and 10.4x higher risk in patients without calcified or noncalcified plaque. Among CAC zero patients who later died of cardiovascular causes, FAI-Score reclassified nearly half as high or very high risk.
Our readGives cardiology and imaging buyers peer reviewed outcome data showing the recently FDA authorized CaRi-Heart adds prognostic value beyond calcium scoring and plaque analysis, which supports the case for adopting it on existing CCTA workflows. The noncontrast CT application described in the same study is investigational and not a shipped capability.